Fig. 1 · Structure

Documents & Downloads

Rilmenidine

Cat. No. A10794 CAS 54187-04-1

α2 adrenergic agonist

Rilmenidine is a second-generation imidazoline-α2 adrenergic agonist.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
K562 IC50 65 μM Antiproliferative activity against human K562 cells assessed as inhibition of cell survival after 48 hrs by MTT assay [PMID: 27265687]

In Vitro Studies

Cultured cortical neurons isolated from Sprague–Dawley rat pups were treated with 1 µm Rilmenidine for 8 h. Western blot analysis showed increased LC3-II levels in non-bafilomycin A1-treated lanes. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Rilmenidine increases LC3-II levels in cultured cortical neurons

Cell-based study · cortical neurons were isolated from embryonic day 16.5 Sprague–Dawley rat pups [1]

Cultured cortical neurons isolated from Sprague–Dawley rat pups were treated with 1 µm Rilmenidine for 8 h. Western blot analysis showed increased LC3-II levels in non-bafilomycin A1-treated lanes.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
LC3-II levels were assessed by western blotReported result 1 µm rilmenidine; non-bafilomycin A1-treated lanes (−Baf A1): treatment with rilmenidine increases LC3-II levels[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 µm
Exposure duration
After 7 days in vitro, cultured neurons were treated for 8 h
Method
cultured neurons were treated
Reported limits
Not stated in the sentences used: vehicle, control.
Methods and source locations

Compound reported in the paper: Rilmenidine

Evidence for Rilmenidine as the hemifumarate form reported in the paper, not the free base/neutral form supplied as A10794; no salt equivalence, dose conversion or lot validation.

RESULTS > Rilmenidine increases autophagy in tissue from wild-type mice (S11); MATERIALS AND METHODS > Cell culture and treatment (S107, S114); Figure 1. legend (S144, S145)

LC3-II levels were assessed by western blot: LC3-II levels were assessed by western blot — RESULTS > Rilmenidine increases autophagy in tissue from wild-type mice (S11); MATERIALS AND METHODS > Cell culture and treatment (S114); Figure 1. legend (S144, S145)

In Vivo Studies

In male SOD1G93A mice, intraperitoneal Rilmenidine significantly decreased survival, objectively defined by the onset of hind limb paralysis, compared with vehicle treatment. In a separate study in male SOD1G93A mice, Rilmenidine increased spinal cord LC3-II levels at symptom onset relative to vehicle treatment. In adult male diabetic Wistar rats, oral Rilmenidine produced a statistically significant reduction in plasma glucose compared with the diabetes + saline group. [2,3]

Rilmenidine and survival in mutant SOD1 mice

Animal study · male SOD1G93A mice; C57BL/6 background; n = 10 mice per group [2]

Male SOD1G93A mice received Rilmenidine by intraperitoneal injection. Survival, objectively defined by the onset of hind limb paralysis, was significantly decreased compared with vehicle-treated mice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
survival objectively defined by the onset of hind limb paralysissurvival 154 ± 6 days[2]

Conditions shared by the study groups

Route
intraperitoneal (i.p.) injections
Treatment course
Starting from postnatal day 60 (P60); 4-times a week
Vehicle
sterile DPBS
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Rilmenidine 10 mg/kgvehicle-treated micesurvival objectively defined by the onset of hind limb paralysis was significantly decreased in rilmenidine-treated mutant SOD1 mice (154 ± 6 days, mean ± SD), compared to vehicle-treated mice (159 ± 6 days) (p<0.05)[2]
Rilmenidine 10 mg/kg
Model: male SOD1G93A mice; C57BL/6 background; n = 10 mice per group
Methods and source locations

Compound reported in the paper: Rilmenidine

Evidence for Rilmenidine as the phosphate form reported in the paper, not the free base/neutral form supplied as A10794; no salt equivalence, dose conversion or lot validation.

Results > Rilmenidine promotes disease progression and augments motor neuron degeneration while having no effect on glial pathology in mutant SOD1 mice (S70); Materials and Methods > Transgenic mice and rilmenidine treatment (S140, S141, S142); Figure 7. legend (S229)

survival objectively defined by the onset of hind limb paralysis: survival objectively defined by the onset of hind limb paralysis; comparator: vehicle-treated mice — Results > Rilmenidine promotes disease progression and augments motor neuron degeneration while having no effect on glial pathology in mutant SOD1 mice (S70)

Rilmenidine 10 mg/kg · Results > Rilmenidine promotes disease progression and augments motor neuron degeneration while having no effect on glial pathology in mutant SOD1 mice (S70); Materials and Methods > Transgenic mice and rilmenidine treatment (S141)

Rilmenidine reduces plasma glucose in diabetic rats

Animal study · male and adult Wistar rats; Diabetic rats; Group 3 (n = 10) [3]

Adult male diabetic Wistar rats received Rilmenidine at 0.2 mg/kg/day by oral gavage. Plasma glucose was 315.4 ± 9.1 mg/dL, a statistically significant reduction compared with the diabetes + saline group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
plasma glucose levelsplasma glucose levels 0.2 mg/kg/day: 315.4 ± 9.1 mg/dL[3]

Conditions shared by the study groups

Route
oral gavage
Treatment course
for four weeks
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Rilmenidine 0.2 mg/kg/daydiabetes + saline treatment groupThe diabetes + 0.2 mg/kg Rilmenidine group had a further reduction, with 315.4 ± 9.1 mg/dL. These differences were statistically significant (p < 0.05) compared to the diabetes + saline group.[3]
Rilmenidine 0.2 mg/kg/day
Model: male and adult Wistar rats; Diabetic rats; Group 3 (n = 10)
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Rilmenidine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Settings > Animals (S2); Methods > Settings > Experimental protocol (S7, S11, S13); Results > Plasma glucose levels (S67, S69, S70)

plasma glucose levels: plasma glucose levels; comparator: diabetes + saline treatment group — Methods > Settings > Experimental protocol (S13); Results > Plasma glucose levels (S69, S70)

Rilmenidine 0.2 mg/kg/day · Methods > Settings > Experimental protocol (S13); Results > Plasma glucose levels (S69, S70)

Rilmenidine and spinal cord LC3-II levels

Animal study · male SOD1G93A mice; C57BL/6 background; n = 3-5 mice [2]

Male SOD1G93A mice received Rilmenidine by intraperitoneal injection. At symptom onset, spinal cord LC3-II levels were higher than in vehicle-treated mice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
LC3-II levelsLC3-II levels 55% higher[2]

Conditions shared by the study groups

Route
intraperitoneal (i.p.) injections
Treatment course
Starting from postnatal day 60 (P60); 4-times a week; collected at symptom onset (P90)
Vehicle
sterile DPBS
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Rilmenidine 10 mg/kgvehicle-treated miceAt symptom onset, LC3-II levels were 55% higher in spinal cords of rilmenidine-treated mice, than in vehicle-treated mice[2]
Rilmenidine 10 mg/kg
Model: male SOD1G93A mice; C57BL/6 background; n = 3-5 mice
Methods and source locations

Compound reported in the paper: Rilmenidine

Evidence for Rilmenidine as the phosphate form reported in the paper, not the free base/neutral form supplied as A10794; no salt equivalence, dose conversion or lot validation.

Results > Rilmenidine enhances MTOR-independent macroautophagy and mitophagy in spinal cords of mutant SOD1 mice (S49, S50); Materials and Methods > Transgenic mice and rilmenidine treatment (S140, S141, S142); Figure 5. legend (S217)

LC3-II levels: LC3-II levels; comparator: vehicle-treated mice — Results > Rilmenidine enhances MTOR-independent macroautophagy and mitophagy in spinal cords of mutant SOD1 mice (S50)

Rilmenidine 10 mg/kg · Results > Rilmenidine enhances MTOR-independent macroautophagy and mitophagy in spinal cords of mutant SOD1 mice (S49, S50); Materials and Methods > Transgenic mice and rilmenidine treatment (S141)

Specifications

Manufacturer Adooq Bioscience
Actions Agonist
CAS Number 54187-04-1
Applications α2 adrenergic agonist
Formula C10H16N2O
Molecular Weight 180.25
Synonyms Tenaxum; HYPERIUM
SMILES
C1CC1C(C2CC2)NC3=NCCO3

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 1 mg/mL (3.59 mM)
Water 47 mg/mL (168.92 mM)
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Rose C, Menzies FM, Renna M, et al. Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's disease. Hum Mol Genet (2010). PMID: 20190273 DOI: 10.1093/hmg/ddq093 Source material
  2. [2] Perera ND, Sheean RK, Lau CL, et al. Rilmenidine promotes MTOR-independent autophagy in the mutant SOD1 mouse model of amyotrophic lateral sclerosis without slowing disease progression. Autophagy (2018). PMID: 28980850 DOI: 10.1080/15548627.2017.1385674 Source material
  3. [3] Yalçın MB, Bora ES, Çakır A, et al. Autophagy and anti-inflammation ameliorate diabetic neuropathy with Rilmenidine. Acta Cir Bras (2023). PMID: 38055406 DOI: 10.1590/acb387823 Source material

Added to your cart

View Cart Checkout
Loading...